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Abstract: Circulating microRNAs (miRNAs) have been implicated in several pathologies including type
1 diabetes. In the present study, we aimed to identify circulating miRNAs affected by disease duration in
children with recent onset type 1 diabetes. Forty children and adolescents from the Danish Remission
Phase Cohort were followed with blood samples drawn at 1, 3, 6, 12, and 60 months after diagnosis.
Pancreatic autoantibodies were measured at each visit. Cytokines were measured only the first year.
miRNA expression profiling was performed by RT-qPCR. The effect of disease duration was analyzed
by mixed models for repeated measurements adjusted for sex and age. Eight miRNAs (hsa-miR-10b-5p,
hsa-miR-17-5p, hsa-miR-30e-5p, hsa-miR-93-5p, hsa-miR-99a-5p, hsa-miR-125b-5p, hsa-miR-423-3p,
and hsa-miR-497-5p) were found to significantly change in expression (adjusted p-value < 0.05) with
disease progression. Three pancreatic autoantibodies, ICA, IA-2A, and GAD65A, and four cytokines,
IL-4, IL-10, IL-21, and IL-22, were associated with the miRNAs at different time points. Pathway analysis
revealed associations with various immune-mediated signaling pathways. Eight miRNAs that were
involved in immunological pathways changed expression levels during the first five years after diagnosis
and were associated with variations in cytokine and pancreatic antibodies, suggesting a possible effect on
the immunological processes in the early phase of the disease.
Keywords: children; immunology; miRNA; partial remission phase; type 1 diabetes
1. Introduction
There is an increased interest in epigenetic mechanisms to understand disease pathogenesis and
progression. Epigenetics involves the heritable modifications of gene expression without changes
in the genome sequence, leading to an altered, sometimes unfavorable, phenotype, e.g., resulting
in metabolic diseases such as diabetes. While it is recognized that a genetic component is essential
to the risk of developing type 1 diabetes (T1D), data from twin studies suggests that genetics alone
cannot explain the disease development [1,2]. Furthermore, the increasing incidence of T1D in younger
children is at a rate which is too fast to be only accounted for by a genetic change. Thus, the role of
other pathogenic influences, such as diet, environment, viral infections, interferons, and epigenetic
modifications, has been suggested to contribute to the development of autoimmune diabetes [3–7].
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MicroRNAs (miRNAs) are small non-coding RNAs with potent post-transcriptional regulatory
properties which have shown potential as biomarkers for different pathophysiologies [8]. During recent
years, the promising features of miRNAs as biomarkers associated with insulin production, residual
β-cell function, and disease complications of diabetes have been investigated [9–11]. The knowledge
emerging on the role of epigenetic control, such as miRNAs, DNA methylation patterns, and histone
modifications, indicates that these regulatory mechanisms have an important function in T1D [12–14].
An important stage in the natural history of T1D is the spontaneous remission phase, which can
be either complete, with temporary insulin independence, or partial. During this phase, which can last
from weeks to several months, a decreased requirement of exogenous insulin is experienced and an
improved metabolic control is observed [15]. The partial remission (PR) phase is a potential temporal
opening for investigating the important immunoregulatory events taking place when the remaining
β-cells are still able to produce enough insulin. Currently, the strategies employed so far have not yet
been able to unravel the underlying mechanisms during this phase, making the development of future
immunotherapies with the capabilities to extend the PR challenging.
Previously, we identified six miRNAs predictive for residual β-cell function and metabolic control in
children newly diagnosed with T1D [11]. In the present study, we hypothesized that circulating miRNAs
reflect the ongoing autoimmune process during the first year after disease onset. Thus, the objective of
this study was to identify circulating miRNAs, which hold the potential to serve as biomarkers for the
autoimmune and immunological status in newly diagnosed children and adolescents with T1D.
2. Results
2.1. Technical Controls Prior to miRNA Profiling
The demographic and anthropometric data characterizing the study cohort is presented in Table 1
and has also recently been described elsewhere [11]. Plasma samples from a subset of children and
adolescents (n = 40) from this cohort collected at different time-points (1, 3, 6, 12, and 60 months) after
diagnosis were subjected to miRNA profiling. The steady expression levels of the RNA spike-ins,
added in the RNA isolation and complementary DNA (cDNA) synthesis steps, indicated that the
processes of RNA extraction, reverse transcription, and qPCR were efficient, and no inhibitors were
present in the samples. Hemolysis of the samples varied between 5 and −2, thus indicating that the
samples were not affected by hemolysis
Table 1. Characteristics of 40 children and adolescents (study population) from the Danish Remission
Phase Cohort and the entire cohort, respectively.
Study Population 1 Month 3 Months 6 Months 12 Months 60 Months
n (girls/n) 40 (24) 37 (22) 33 (19) 34 (20) 38 (23)
Age at diagnosis (years) 8.7 (3.4) - - - -
HbA1c (DCCT, %) 9.1 (1.3) 7.3 (1.1) 7.8 (1.6) 7.9 (1.1) 8.4 (1.0)
HbA1c (IFCC,mmol/mol) 76 (14.2) 56 (12.0) 62 (17.5) 63 (12.0) 68 (11.0)
C-peptide (pmol/L) 629 (371) 528 (323) 436 (333) 257 (251) 62 (76)
IDAA1c 10.8 (2.0) 9.2 (1.5) 10.1 (2.2) 11.0 (1.8) 12.0 (1.9)
Insulin dose (units/kg/24 h) 0.45 (0.27) 0.47 (0.23) 0.58 (0.26) 0.78 (0.27) 0.88 (0.32)
Autoantibody positivity (%)
GAD65A 55 62 61 56 55
IA 80 100 100 100 78
IA-2A 73 68 70 68 74
ICA 93 92 94 94 92
ZnT8tripleAb 65 70 75 76 26
Data are presented as means (SD), unless otherwise stated. SCP: stimulated C-peptide. IDAA1c = HbA1c (percent)
+ [4 × insulin dose (units per kilogram per 24 h)]. GAD65A: autoantibodies against glutamic acid decarboxylase
(GAD). IA: insulin autoantibodies. IA-2A: islet antigen 2 antibody. ICA: islet-cell antibody. ZnT8tribleAb:
Zinc transporter 8 triple mix antibody variant containing the isotypes glutamine, arginine, and tryptophan.
Missing data are either due to no visit, missing or lost sample, or drop-out.
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2.2. miRNA Quantification in 182 Plasma Samples
A selected panel of 179 human serum/plasma miRNAs was analyzed over the five time points
after diagnosis. An average of 163 miRNAs were quantified and 100 were quantified in all samples.
2.3. Effect of Disease Duration on miRNA Expression Levels during the First Five Years after Diagnosis
Analysis by mixed model for repeated measurements indicated that 28 miRNAs varied
in expression levels during the first five years after diagnosis (p < 0.05). After correcting for
multiple testing, eight miRNAs (hsa-miR-10b-5p, hsa-miR-17-5p, hsa-miR-30e-5p, hsa-miR-93-5p,
hsa-miR-99a-5p, hsa-miR-125b-5p, hsa-miR-423-3p, and hsa-miR-497-5p) showed variations in
expression levels during the first five years after disease onset (p < 0.05) (Table 2). The results of
these eight candidate miRNAs were adjusted for age and sex. After adjustments, the data revealed that
age only had an effect on hsa-miR-423-3p (p = 0.0088, data not shown). Neither HbA1c nor stimulated
C-peptide (SCP) correlated with any of the quantified miRNAs. The average expression levels of the
eight candidate miRNAs with altered expression levels during the first five years are shown as a heat
map in Figure 1.
Figure 1. The eight candidate microRNAs (miRNAs) with changing expression levels during the
first five years after diagnosis. The normalized expression (∆Cp) values of the miRNAs at different
time-points are clustered based on the distance measure (which is calculated as 1-cor) and transformed
into Z-scores. cor = Pearson’s correlation coefficient.
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Table 2. Effect of disease duration on miRNA expression level.
miRNA Unadjusted p-Value Adjusted p-Value
hsa-miR-99a-5p <0.00001 0.00022
hsa-miR-30e-5p <0.00001 0.00027
hsa-miR-497-5p <0.00001 0.00041
hsa-miR-10b-5p 0.00001 0.00072
hsa-miR-423-3p 0.00001 0.00131
hsa-miR-125b-5p 0.00003 0.00252
hsa-miR-17-5p 0.00011 0.01057
hsa-miR-93-5p 0.00012 0.01094
hsa-miR-146a-5p 0.00094 0.08678
hsa-miR-484 0.00195 0.17716
hsa-miR-185-5p 0.00208 0.18726
hsa-miR-24-3 0.00291 0.25943
hsa-miR-660-5p 0.00944 0.83059
hsa-miR-25-3p 0.01088 0.94673
hsa-let-7b-5p 0.01133 0.97420
hsa-miR-320a 0.01236 0.98546
hsa-miR-223-3p 0.01248 0.98546
hsa-let-7g-5p 0.01553 0.98546
hsa-miR-20a-5p 0.01815 0.98546
hsa-let-7i-5p 0.02298 0.98546
hsa-miR-142-3p 0.02412 0.98546
hsa-miR-32-5p 0.02544 0.98546
hsa-miR-486-5p 0.02989 0.98546
hsa-miR-142-5p 0.04400 0.98546
hsa-miR-320b 0.04421 0.98546
hsa-miR-145-5p 0.04545 0.98546
hsa-miR-221-3p 0.04598 0.98546
hsa-miR-106a-5p 0.04701 0.98546
The table shows the 28 statistically significant miRNAs values with altered expressed levels among 100 miRNAs
investigated during the observation time before correction for multiple testing and after correction (n = 8), sorted
according to the lowest adjusted p-value.
The normalized expression (global mean method and adjusted for age and sex) levels (∆Cp)
of hsa-miR-17-5p, hsa-miR-30e-5p, hsa-miR-93-5p, and hsa-miR-423-3p declined within the first
12 months after diagnosis and subsequently increased from one to five years after diagnosis. By contrast,
the levels of hsa-miR-10b-5p, hsa-miR-99a-5p, hsa-miR-125b-5p, and hsa-miR-497-5p increased
during the first 12 months and subsequently decreased between one and five years after diagnosis.
Five miRNAs (hsa-miR-10b-5p, hsa-miR-17-5p, hsa-miR-99a-5p, hsa-miR-125b-5p, and hsa-miR-497-5p)
were expressed with a lower ∆Cp value compared to the average of all samples at each time point,
and the remaining three miRNAs (hsa-miR-30e-5p, hsa-miR-93-5p, and hsa-miR-423-3p) were more
abundantly expressed compared to the average of all samples at all time-points (Figure 1 and Table S1).
2.4. Identification of miRNA Target Genes
The target genes for the eight candidate miRNAs were retrieved from two sources:
miRTarBase [16] and TargetScan [17] using cyTargetLinker [18]. In total, 996 target genes for eight
miRNAs as predicted by both tools were used for further analysis (Table S1). The pathway enrichment
analysis was performed using PantherDB [19]. The pathway analysis revealed enrichment of various
signaling pathways including epidermal growth factor (EGF), fibroblast growth factor (FGF), integrin,
platelet-derived growth factor (PDGF), transforming growth factor (TGF) β, and apoptosis signaling
pathways, as shown in Table 3. The detailed pathway analysis including the enriched target genes
associated with each pathway are listed (Table S2).
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Table 3. Enriched pathways associated with the validated target genes of the eight miRNAs with
altered expression levels during the first five years after diagnosis.
Panther Pathways Fold Enrichment p-Value miRNAs
Angiogenesis 3.37 8.25 × 10−6 hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-17-5p,hsa-miR-423-3p, hsa-miR-93-5p, hsa-miR-99a-5p
Gonadotropin-releasing hormone
receptor pathway 2.9 1.77 × 10
−5
hsa-miR-17-5p, hsa-miR-125b-5p, hsa-miR-497-5p,
hsa-miR-423-3p, hsa-miR-10b-5p, hsa-miR-93-5p,
hsa-miR-30e-5p, hsa-miR-99a-5p
TGF-β signaling pathway 4.08 7.21 × 10−5 hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-17-5p,hsa-miR-423-3p, hsa-miR-93-5p, hsa-miR-99a-5p
CCKR signaling map 3.11 1.07 × 10−4
hsa-miR-17-5p, hsa-miR-125b-5p, hsa-miR-497-5p,
hsa-miR-93-5p, hsa-miR-99a-5p, hsa-miR-10b-5p,
hsa-miR-423-3p
EGF receptor signaling pathway 3.12 1.16 × 10−3
hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-17-5p,
hsa-miR-423-3p, hsa-miR-497-5p, hsa-miR-93-5p,
hsa-miR-99a-5p
PDGF signaling pathway 2.91 3.16 × 10−3
hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-17-5p,
hsa-miR-423-3p, hsa-miR-497-5p, hsa-miR-93-5p,
hsa-miR-99a-5p
Apoptosis signaling pathway 3.12 5.05 × 10−3 hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-17-5p,hsa-miR-30e-5p, hsa-miR-423-3p, hsa-miR-93-5p
FGF signaling pathway 3.05 6.90 × 10−3
hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-17-5p,
hsa-miR-423-3p, hsa-miR-497-5p, hsa-miR-93-5p,
hsa-miR-99a-5p
p53 pathway feedback loops 2 4.49 7.85 × 10−3 hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-17-5p,hsa-miR-423-3p, hsa-miR-93-5p, hsa-miR-99a-5p
Ras Pathway 3.66 1.34 × 10−2 hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-17-5p,hsa-miR-423-3p, hsa-miR-497-5p, hsa-miR-93-5p
Integrin signalling pathway 2.41 3.07 × 10−2
hsa-miR-10b-5p, hsa-miR-125b-5p, hsa-miR-17-5p,
hsa-miR-423-3p, hsa-miR-497-5p, hsa-miR-93-5p,
hsa-miR-99a-5p
The enriched pathways are listed for the validated targets of the eight candidate miRNAs which changed in
expression level over time. The fold enrichment and p-values were calculated using the binomial test. The p-values
were adjusted for multiple correction using the Bonferroni method. TGF: transforming growth factor. CCKR:
cholecystokinin receptors 1 and 2. EGF: epidermal growth factor. PDGF: platelet-derived growth factor. FGF:
fibroblast growth factor. IGF: insulin-like growth factor.
2.5. Partial remission and Immunological Status
Using the new definition for PR with IDAA1c ≤ 9 in the study population of 40 children and
adolescents, 19 (51%) children were in PR 3 months after diagnosis, and 4 (12%) and 1 (3%) were in PR
after 12 and 60 months, respectively.
Of the five autoantibodies tested, seroconversion was most profound for ZnT8tripleAb during the
study period. Insulin antibodies (IA) increased from 80 to 100% during the first year after diagnosis
(Table 1) and remained positive in all the children between three and twelve months in the study
population and the study cohort. Seroconversion for IA was observed in twenty-two percent of the
children five years after diagnosis (Table 1). The Spearman correlation analysis performed on the
association of the eight candidate miRNAs and the anti-islet autoantibodies measurements showed that
three of the candidate miRNAs were statistically significantly (p < 0.036) associated with the measured
autoantibodies before correcting for multiple testing. Islet-cell autoantibodies (ICA) were negatively
associated with hsa-miR-99a-5p at 3 months after diagnosis. At the same time point, ICA and IA-2A
were negatively associated with hsa-miR-125b-5p. Finally, GADA65 was positively associated with
hsa-miR-17-5p 6 months after diagnosis (Table 4).
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Table 4. Association between the eight candidate miRNAs and autoantibodies titers.
Months after Diagnosis miRNA Autoantibody Spearman Correlation (rs)
Unadjusted
p-Value
Adjusted
p-Values
3 hsa-miR-99a-5p ICA −0.35 0.036 N/S
3 hsa-miR-125b-5p ICA −0.36 0.030 N/S
3 hsa-miR-125b-5p IA-2A −0.35 0.032 N/S
6 hsa-miR-17-5p GADA 0.37 0.033 N/S
The association between the eight candidate miRNAs and autoantibody titers measured at the five time points
after diagnosis by Spearman correlation (rs). Only the statistically significant associations are shown (p ≤ 0.05).
The significant values are before correcting for multiple testing. After correction, no significant association was seen
(N/S). GAD65A: autoantibodies against antigen GAD. IA-2A: islet antigen 2. ICA: Islet-cell antibody. ZnT8: zinc
transporter 8 (triple mix antibodies containing the isotypes glutamine, arginine, and tryptophan).
2.6. Association of the Eight Candidate miRNAs to Cytokines
The Spearman correlation analysis performed between the eight candidate miRNAs and
35 measured cytokines at 1, 3, 6, and 12 months after diagnosis showed, before correction for multiple
testing, that hsa-miR-10b-5p correlated negatively with IL-21 (r = −0.63, p = 0.0051) at 3 months,
whereas hsa-miR-17-5p at 1 month correlated positively with IL-21 (r = 0.62, p = 0.0048). Likewise,
hsa-miR-17-5p was positively associated with IL-10 and IL-4 at 1 month (r = 0.68, p = 0.0015; r = 0.70,
p = 0.0008; respectively). Finally, hsa-miR-30e-5p correlated positively with IL-22 at 6 months (r = 0.71,
p = 0.0015).
3. Discussion
Aberrantly circulating miRNA levels in plasma, serum, and urine samples from children
with T1D were assessed recently by Osipova et al. [20], and the number of studies exploring the
prognostic potential of miRNAs in different settings is steadily increasing [21–23]. Our group
recently showed, in the same cohort as the one used in present study, that six miRNAs predicted
stimulated C-peptide, HbA1c, and the insulin dose adjusted HbA1c (IDAA1c) the first year after disease
onset [11]. In the present study, we identified miRNAs with expression levels that were influenced
by disease progression, but not associated to the decline in β-cell function. In this prospective study,
disease progression had a statistically significant effect on the expression levels of eight candidate
miRNAs, irrespective of age and sex. Further bioinformatics evaluation of the validated targets of
these miRNAs and the observed cytokine and pancreatic antibody associations support a possible
immunological impact reflected by circulating miRNAs during the PR. However, cytokine profiles
were only quantified in about half of the study participants in the Danish Remission Phase Cohort
due to technical reasons. Thus, the study was under-powered for fully exploring these potential
associations. The pathway-based analysis identified highly significant pathways associated with the
target genes of eight miRNA candidates. The top highly significant pathways included angiogenesis,
TGF-β, cholecystokinin receptor (CCKR), EGF, PDGF, apoptosis, FGF, integrin signaling, and the Ras
pathway. STAT3, a potential target gene for hsa-miR-93-5p and hsa-miR-125b-5p, is associated with
angiogenesis, the Ras pathway, EGF receptor signaling, CCKR signaling, and PDGF signaling pathways.
MTOR (a serine/threonine protein kinase), which is a target gene for hsa-miR-99a-5p, is associated
with the PDGF signaling pathway. MTOR is a central regulator of cellular metabolism, growth,
and survival [24]. The activation of MTOR regulates various effector functions of CD4+ and CD8+ T
cells, and MTOR inhibitors (i.e., rapamycin) are used as potential immunosuppressive therapeutics for
organ transplants, metabolic diseases, and various autoimmune disorders [25]. Furthermore, MTOR
has been demonstrated to be involved in the onset and progression of autoimmune disorders including
diabetes [26]. PIK3CD, a target gene for hsa-miR-10b-5p is a known mediator of immune responses
and is associated with several pathways including angiogenesis, apoptosis signaling, EGF receptor
signaling, PDGF signaling, FGF signaling, integrin signaling, and the Ras pathway.
One of the strengths of this study was the phenotypically thorough characterization of the
study participants who were followed with repeated measurements initially after diagnosis and
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during the first five years thereafter. The present study also provides data from pathway analysis
together with cytokine and pancreatic antibody variations associated with miRNAs during PR to
suggest that miRNAs regulating genes that control immune recognition could be involved in the
autoimmune processes during the initial progression of the disease. In our previous study [11],
six miRNAs analyzed in the same population could predict residual β-cell function and glycemic
control (SCP, HbA1c, and IDAA1c) in children with new onset T1D the first five years after diagnosis.
Accumulating evidence supports that miRNAs play a crucial role in the regulation of pancreatic
β-cell function under normal and pathophysiological conditions, such as insulin biosynthesis, insulin
exocytosis, and β-cell expansion, and may have clinical significance in diabetes [11,27]. The current
study further provides data, in the same study population, on different miRNAs, which change
expression levels during the first five years after diagnosis and have a possible involvement in
immunological pathways. Three pancreatic autoantibodies, ICA, IA-2A, and GADA65, and four
cytokines, IL-4, IL-10, IL-21, and IL-22, were associated with the miRNAs at different time points.
Interestingly, hsa-miR-17-5p correlated with interleukin-4 and interleukin-10 levels, which have
anti-inflammatory effects and dampens the autoimmune process. However, these stratifications were
under-powered due to limited sample sizes and the limited number of study participants who were
followed five years after diabetes diagnosis. This decreased the statistical power to conclude on the
potential role of the eight candidate miRNAs during the PR. The observed variability of the candidate
miRNAs need further validation in larger cohorts, and their immunological function in autoimmune
diabetes also needs to be elucidated in further detail.
In conclusion, this study identified eight circulating miRNAs that changed in expression levels,
irrespective of age and sex, during the first five years after diabetes diagnosis, which have the potential
to be used as biomarkers for the immunological progression and definition of the optimal state for
immune intervention during the initial phase of T1D.
4. Materials and Methods
4.1. Study Population and Samples
The Danish Remission Phase Cohort comprised 129 children (66 boys) with T1D. The study
was a longitudinal multicenter investigation conducted in four pediatric out-patient clinics with
enrolment during the years 2004 to 2005. Plasma samples were drawn on fasting state after a meal
stimulation test at 1, 3, 6, 12, and 60 months after diagnosis and stored in a bio-bank at −80 ◦C until
further use. Diabetes diagnosis was classified according to the World Health Organization criteria [28].
The reasons for drop-outs from the cohort or loss of follow up at the 5-year visit were either adolescents
transferred to adult clinics, changed residences, or unwillingness to participate. The exclusion criteria
were suspicions of other types of diabetes (maturity-onset diabetes of the young (MODY), type 2
diabetes, or secondary diabetes) and/or if patients were initially treated outside the center for more
than five days. The 40 participants who completed the follow-up at five years diabetes duration
were slightly younger with a lower body mass index (BMI) and had lower postprandial C-peptide
levels 12 months after diagnosis compared to the full cohort, but they were similar in terms of sex
distribution, HbA1c, and hormone levels. The study was performed according to the criteria of the
Helsinki II Declaration and was approved by the Danish National Committee on Biomedical Research
Ethics (Journal number: H-KA-04010-m). Older children gave their assent and all parents or guardians
gave written informed consent.
4.2. Partial Remission (PR) Phase
Different definitions for the PR phase have been suggested. Previously, it was defined as HbA1c
near or within the normal range and a daily insulin dose requirement of <0.5 units/kg/day [29].
A new definition combining both values has recently been proposed: insulin dose-adjusted HbA1c,
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and IDAA1c, which suggests that a value ≤9 indicates partial remission [30,31]. This definition has
been recommended by the International Society for Pediatric and Adolescent Diabetes (ISPAD) [32].
4.3. Pancreatic Anti-Islet Autoantibodies
Islet autoantibody measurements were measured in serum samples from all included children
in the Danish Remission Phase Cohort. Titers of the anti-islet autoantibodies (insulin antibodies
(IA), insulinoma associated antigen-2 autoantibody (IA-2A), autoantibodies against glutamic acid
decarboxylase (GAD65A), and islet-cell autoantibodies (ICA)) were analyzed at 1, 3, 6, 12,
and 60 months after diagnosis according to the methods described earlier [33]. The zinc transporter 8
variant containing all three isotypes arginine, tryptophan, and glutamine (ZnT8RWQ or ZnT8tripleAb)
were analyzed by a so called triple mix radioligand binding assay (RBA) as previously described [34,35]
at the time points 1, 3, 6, and 12 months after diagnosis. Another method was used for analyzing the
"triple mix" ZnT8 autoantibodies (ZnT8tripleAb) 60 months after diagnosis [36].
The cut-off values for anti-islet autoantibody positivity were 5.36 relative units (RU) for GAD65A,
0.77 RU for IA-2A, 2.5 Juvenile Diabetes Foundation units (JDFU) for ICA, and 2.80 RU for IA.
The cut-off limit for the triple mix assay, used the first year after diagnosis, was 58 U/mL, and for the
assay by Salonen et al. [36] used five years after diagnosis, the cut-off value was set to 0.61 RU.
4.4. Cytokine Measurements
Cytokine status was measured for half of the recruited study participants in the Danish Remission
Phase Cohort at 1, 3, 6, and 12 months after diagnosis. Cytokine measurements were performed
using an in-house-developed and -validated multiplex immunoassay (Laboratory of Translational
Immunology, University Medical Center, Utrecht, The Netherlands) based on Luminex technology
(xMAP, Luminex, Austin TX, USA) [37].
4.5. miRNA Expression Profiling and Normalization Method
miRNAs were quantified from a total of 182 plasma samples drawn from the subgroup of
40 children and adolescents who participated in the 5-year visit. RNA extraction was performed using
the miRCURYTM RNA Isolation Kit-Biofluids and RT-qPCR was performed with ExiLENT SYBR®
Green Master Mix according to the manufacturer’s instructions (Exiqon A/S, Vedbaek, Denmark).
All RT-qPCR assays were performed in a LightCycler480® Real-Time PCR System in 384 well plates
(Roche, Hvidovre, Denmark). Quality control was done on a subset of samples (n = 10) with synthetic
spike-in RNAs as a quality control of the RNA isolation and cDNA synthesis. A detailed description
of the RNA isolation and quality control procedure is outlined in [9]. Assessment of hemolysis
was evaluated by comparing the levels of hsa-miR-451a (miRNA highly expressed in erythrocytes)
with hsa-miR-23a-3p (stable in plasma/serum and not affected by hemolysis) as described by
Blondal et al. [38].
Each plasma sample was run on a selected assay containing a panel of 179 predefined human
serum/plasma miRNAs (V3; Exiqon), including miRNAs known to be involved in immunological
and metabolic diseases. The 100 miRNAs with complete data that were quantified in all samples
in the miRNA expression profiling were employed for the normalization of data using the global
mean method, since this approach has been shown to be the most stable normalizer according to
Mestdagh et al. [39]. The formula used to calculate the normalized Cp values was:
∆Cp = average Cp (all samples) − assay Cp (sample)
4.6. Validation of Target Genes and Pathway Analysis
The validated and predicted target genes for the eight candidate miRNAs found in this study were
retrieved from two sources: miRTarBase [16] (experimentally verified miRNA interactions retrieved
from automated text mining in PubMed) and TargetScan [17] (predicted miRNA interactions) using
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the cyTargetLinker app in CytoScape [18]. The pathway-based enrichment analysis was performed
using PantherDB [19]. The p-values were calculated using the binomial test and adjusted for multiple
corrections using the Bonferroni method.
4.7. Statistical Analysis
All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
The miRNA levels with complete data were included for analysis and were managed on a base-2
logarithmic scale (log2). The influence of diabetes duration on circulating levels of miRNAs were
analyzed by a linear mixed model for repeated measurements including the covariates for sex and
age at the visit (to account for the potential age development) and with an unstructured covariance
matrix. p-Values for the differentially expressed miRNAs associated with disease duration were further
adjusted according to the Hochberg approach (p < 0.05). For antibodies and cytokines, the Spearman
correlation analysis used the measured values and included values below the detection limit as a value
below all others; it was performed to determine the relationship between variables and was considered
significant with a corresponding p ≤ 0.05.
Supplementary Materials: The following are available online at http://www.mdpi.com/2311-553X/4/4/35/s1,
Table S1: ∆Cp values of 8 miRNAs at different time-points and Table S2: Pathway-based enrichment analysis
using PantherDB.
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